The healthcare technology leader Tempus recently announced a significant financial milestone for the fiscal year 2025. The company reported a record Tempus Total Contract Value (TCV) that exceeded $1.1 billion. This figure represents a major achievement for the firm as of December 31, 2025. This growth highlights the rising demand for data-driven insights in the medical field. The company continues to lead the way in the application of artificial intelligence.
The business focuses on helping physicians make better decisions through advanced data analysis. They use a vast library of clinical and molecular data to personalize patient care. This record Tempus Total Contract Value (TCV) shows the strong trust from over 70 biopharma partners. These partners include global giants like AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs including Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics. The company reported a preliminary net revenue retention of approximately 126% in 2025. This demonstrates a deep expansion of relationships with its existing customers.
Expansion of AI-Driven Precision Medicine Services
The firm is scaling its operations to meet the needs of modern oncology. They provided preliminary data showing 31% year-over-year growth in their data and application revenue. The growth in the Tempus Total Contract Value (TCV) is a sign of a trend towards precision medicine. Increasingly, more providers of health care are using such health care software. All this is expected to make the success of the company even better in the coming year.
“2025 was a record year for our Data and applications business – both from a revenue and TCV perspective. Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond,” said Jim Rogers, Chief Financial Officer at Tempus.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
